LCLA.FFrankfurt
PT Kalbe Farma Tbk.
€0.03
ListedDec 23, 2005
SectorHealthcare
IndustryDrug Manufacturers — General
CountryIndonesia
Employees12895
State-| CityJakarta| AddressGedung KALBE| Phone62 21 4287 3888
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. The company was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Key Indicators

Key financial and dividend metrics for this stock.

?
P/E Ratio
0.0
?
Div. Rate
€0.00
?
Div. Yield
3.03%
?
Payout Ratio
45.18%
?
Max Consec. Div. Years
19 years
?
Longest Consec. Div.
19 years
?
Div. Coverage
95%
?
Div. Stability Rate
0.12
?
Div. Growth Rate
75.00%
?
Score
90

Dividend History

Historical dividend payments by ex-dividend date.

Jun 4, 2025
€ 0.0017
May 29, 2024
€ 0.0015
May 12, 2023
€ 0.0018
May 31, 2022
€ 0.0017
Jun 8, 2021
€ 0.0013
Dec 4, 2020
€ 0.0003
Jun 2, 2020
€ 0.0010
Jun 10, 2019
€ 0.0012
Jun 22, 2018
€ 0.0012
Jun 13, 2017
€ 0.0011
Jun 8, 2016
€ 0.0009
May 26, 2015
€ 0.0009
Jun 16, 2014
€ 0.0008
Jun 14, 2013
€ 0.0009
Jun 29, 2012
€ 0.0009
Jun 28, 2011
€ 0.0007
Jul 16, 2010
€ 0.0002
Jul 30, 2009
€ 0.0001
Aug 1, 2008
€ 0.0001
Jun 15, 2007
€ 0.0001

Peer Companies

Other stocks in the same sector.

The app download will be available in the next version. Stay tuned!